BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15255551)

  • 1. Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer?
    Lopez JB; Sahabudin RM; Chin LP
    Int J Biol Markers; 2004; 19(2):164-7. PubMed ID: 15255551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
    Khosravi J; Diamandi A; Mistry J; Scorilas A
    J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F
    Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated insulin and reduced insulin like growth factor binding protein-3/prostate specific antigen ratio with increase in prostate size in Benign Prostatic Hyperplasia.
    Sreenivasulu K; Nandeesha H; Dorairajan LN; Rajappa M; Vinayagam V
    Clin Chim Acta; 2017 Jun; 469():37-41. PubMed ID: 28300542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y; Sakai H; Hayashi T; Kanetake H
    Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3.
    Safarinejad MR; Shafiei N; Safarinejad S
    Growth Horm IGF Res; 2011 Jun; 21(3):146-54. PubMed ID: 21536469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score.
    Correa LL; Neto LV; Lima GA; Gabrich R; Miranda LC; Gadelha MR
    Int Braz J Urol; 2015; 41(1):110-5. PubMed ID: 25928516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
    Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
    Stattin P; Bylund A; Rinaldi S; Biessy C; Déchaud H; Stenman UH; Egevad L; Riboli E; Hallmans G; Kaaks R
    J Natl Cancer Inst; 2000 Dec; 92(23):1910-7. PubMed ID: 11106682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The correlation between zinc and insulin-like growth factor 1 (IGF-1), its binding protein (IGFBP-3) and prostate-specific antigen (PSA) in prostate cancer.
    Daragó A; Sapota A; Matych J; Nasiadek M; Skrzypińska-Gawrysiak M; Kilanowicz A
    Clin Chem Lab Med; 2011 Oct; 49(10):1699-705. PubMed ID: 21671822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples.
    Ismail HA; Pollak M; Behlouli H; Tanguay S; Bégin LR; Aprikian AG
    BJU Int; 2003 Nov; 92(7):699-702. PubMed ID: 14616449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum IGF-binding protein-6 and prostate specific antigen in breast cancer.
    Kaulsay KK; Ng EH; Ji CY; Ho GH; Aw TC; Lee KO
    Eur J Endocrinol; 1999 Feb; 140(2):164-8. PubMed ID: 10069662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy.
    Ismail A H; Pollak M; Behlouli H; Tanguay S; Begin LR; Aprikian AG
    J Urol; 2002 Dec; 168(6):2426-30. PubMed ID: 12441932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence.
    Yu H; Nicar MR; Shi R; Berkel HJ; Nam R; Trachtenberg J; Diamandis EP
    Urology; 2001 Mar; 57(3):471-5. PubMed ID: 11248622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen.
    Finne P; Auvinen A; Koistinen H; Zhang WM; Määttänen L; Rannikko S; Tammela T; Seppälä M; Hakama M; Stenman UH
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2744-7. PubMed ID: 10946875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection.
    Stattin P; Stenman UH; Riboli E; Hallmans G; Kaaks R
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5745-8. PubMed ID: 11739433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
    Janssen JA; Wildhagen MF; Ito K; Blijenberg BG; Van Schaik RH; Roobol MJ; Pols HA; Lamberts SW; Schröder FH
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4391-6. PubMed ID: 15356036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
    Zhigang Z; Jieming L; Su L; Wenlu S
    J Surg Oncol; 2007 Jul; 96(1):54-61. PubMed ID: 17345593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.